Tissue platinum concentration and tumor response in non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3345-3352

  Kim, Eric S ^a   Lee, J Jack ^a   He, Guangan ^a   Chow, Chi Wan ^a   Fujimoto, Junya ^a   Kalhor, Neda ^a   Swisher, Stephen G ^a   Wistuba, Ignacio I ^a   Stewart, David J ^a   Siddik, Zahid H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM;

ADULT; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TISSUE LEVEL; FEMALE; FLAMELESS ATOMIC ABSORPTION SPECTROPHOTOMETRY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PLATINUM; SURVIVAL ANALYSIS;

EID: 84866760400     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.8120     Document Type: Article

References (43)

1. Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003 (Pubitemid 37487159)
2. Hoang T, Xu R, Schiller JH, et al: Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 23:175-183, 2005 (Pubitemid 41702636)
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
4. Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75:173-234, 2010
5. Gately DP, Howell SB: Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer 67:1171-1176, 1993 (Pubitemid 23172848)
6. Andrews PA, Howell SB: Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells 2:35-43, 1990 (Pubitemid 20218552)
7. Shellard SA, Fichtinger-Schepman AM, Lazo JS, et al: Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4:491-500, 1993 (Pubitemid 23253708)
8. Shimura M, Saito A, Matsuyama S, et al: Element array by scanning X-ray fluorescence microscopy after cis-diamminedichloro-platinum(II) treatment. Cancer Res 65:4998-5002, 2005 (Pubitemid 40827304)
9. Kawai H, Kiura K, Tabata M, et al: Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 35:305-314, 2002 (Pubitemid 34158665)
10. Matsumura T, Takigawa N, Kiura K, et al: Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: Evidence of cisplatin accumulation and topoisomerase I activity. In Vivo 19:717-721, 2005
11. Bungo M, Fujiwara Y, Kasahara K, et al: Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human nonsmall cell lung cancer cell lines: Relation to DNA damage and repair. Cancer Res 50:2549-2553, 1990 (Pubitemid 20150181)
12. Poirier MC, Reed E, Litterst CL, et al: Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52:149-153, 1992
13. Stewart DJ, Benjamin RS, Luna M, et al: Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol 10:51-54, 1982 (Pubitemid 13167317)
14. Pataer A, Kalhor N, Correa AM, et al: Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7:825-832, 2012
15. Siddik ZH, Boxall FE, Harrap KR: Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem 163:21-26, 1987 (Pubitemid 17087549)
16. Verschraegen CF, Kumagai S, Davidson R, et al: Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol 129:549-555, 2003 (Pubitemid 37363593)
17. Eisenhauer EA, Therasse P, Bogaerts J, et al: New Response Evaluation Criteria in Solid Tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
18. Los G, Verdegaal E, Noteborn HP, et al: Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol 42:357-363, 1991
19. Gregg RW, Molepo JM, Monpetit VJ, et al: Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10:795-803, 1992
20. Stewart DJ, Dulberg C, Molepo JM, et al: Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration. Cancer Chemother Pharmacol 34:14-22, 1994 (Pubitemid 24194553)
21. Stewart DJ, Mikhael NZ, Nanji AA, et al: Renal and hepatic concentrations of platinum: Relationship to cisplatin time, dose, and nephrotoxicity. J Clin Oncol 3:1251-1256, 1985 (Pubitemid 15226531)
22. Stewart DJ, Molepo JM, Green RM, et al: Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 71:598-604, 1995
23. Stewart DJ, Mikhael NZ, Nair RC, et al: Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol 11:152-158, 1988 (Pubitemid 18099010)
24. Henness S, Davey MW, Harvie RM, et al: Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys 54:895-902, 2002
25. Oguri T, Isobe T, Fujitaka K, et al: Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer 93:584-589, 2001 (Pubitemid 32701419)
26. Oguri T, Isobe T, Suzuki T, et al: Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int J Cancer 86:95-100, 2000 (Pubitemid 30133993)
27. Ikuta K, Takemura K, Sasaki K, et al: Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 28:707-712, 2005 (Pubitemid 40879942)
28. Yoh K, Ishii G, Yokose T, et al: Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10:1691-1697, 2004 (Pubitemid 38435560)
29. Kawasaki M, Nakanishi Y, Kuwano K, et al: Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34:1352-1357, 1998 (Pubitemid 28370925)
30. Miyatake K, Gemba K, Ueoka H, et al: Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res 23:2829-2836, 2003 (Pubitemid 36969820)
31. Komatsu M, Sumizawa T, Mutoh M, et al: Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60:1312-1316, 2000 (Pubitemid 30152000)
32. Nakagawa T, Inoue Y, Kodama H, et al: Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol Rep 20:265-270, 2008
33. Chen HH, Yan JJ, Chen WC, et al: Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75:228-234, 2012
34. Stewart DJ, Chiritescu G, Dahrouge S, et al: Chemotherapy dose-response relationships in nonsmall cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 33:101-137, 2007 (Pubitemid 46343105)
35. Stewart DJ, Raaphorst GP, Yau J, et al: Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: A hypothesis. Invest New Drugs 14:115-130, 1996 (Pubitemid 26340680)
36. Laurencot CM, Kennedy KA: Influence of pH on the cytotoxicity of cisplatin in EMT6 mouse mammary tumor cells. Oncol Res 7:371-379, 1995
37. Koukourakis MI, Giatromanolaki A, Sivridis E: Lactate dehydrogenase isoenzymes 1 and 5: Differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol 24:199-202, 2003 (Pubitemid 37500569)
38. Shannon AM, Bouchier-Hayes DJ, Condron CM, et al: Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma. Br J Cancer 93:224-232, 2005 (Pubitemid 41133209)
39. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331-344, 1998
40. Li Q, Yu JJ, Mu C, et al: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20:645-652, 2000 (Pubitemid 30240614)
41. Yoshida M, Khokhar AR, Siddik ZH: Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Cancer Res 54:3468-3473, 1994 (Pubitemid 24225968)
42. Stewart DJ, Tomiak E, Shamji FM, et al: Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 44:241-249, 2004 (Pubitemid 38482057)
43. Vergote I, Trop é CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953, 2010